Occurrence Delays of Metastatic Relapses of Breast Cancers Treated at University Hospital of Treichville (Abidjan-Cote d’Ivoire) — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Occurrence Delays of Metastatic Relapses of Breast Cancers Treated at University Hospital of Treichville (Abidjan-Cote d’Ivoire)
Department of Gynecology and Obstetrics, University Hospital of Bouaké, Bouake, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
,
Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
1 Department of Gynecology and Obstetrics, University Hospital of Bouaké, Bouake, Cote d’Ivoire
2 Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
3 Department of Gynecology and Obstetrics, University Hospital of Cocody, Abidjan, Cote d’Ivoire
4 Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
5 Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
6 Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
7 Department of Gynecology and Obstetrics, University Hospital of Treichville, Abidjan, Cote d’Ivoire
Objective: Describe the occurrence delays of metastatic relapses of breast cancer based on the characteristics of the original tumor. Methodology : This is a retrospective and cohort study conducted from January 2000 to December 2015 on patients with metastatic relapse of breast cancer. Results : Out of 178 patients collected, the metastatic relapses were estimated at 49%, occurring in patients with an average age of 53.4 years. The majority of the patients was educated (91.6%) and did not have a high socioeconomic level (88.2%). The initial tumors were mainly at a clinical stage III (47.8%), SBR grade III (47.2%), high index Ki 67 (46.5%), negative RH (79.3%) and HER2 negative (58%). Metastases were unique in general (62.9%), dominated by bone locations (36.6%), with an average age of occurrence of 2.4 years. After the occurrence of these metastases, the cumulative survival rate was 5% at 3 years, and zero to 5 years. Conclusion: Metastatic relapses were common with poor prognosis.
Toure, M., Nguessan, E., Bambara, A.T., Kouassi, Y.K.K., Dia, J.M.L. and Adoubi, I. (2013) Factorslinked to Late Diagnosis in Breast Cancer in Sub-Saharan Africa: Case of Cote d’Ivoire. Gynécologie Obstétrique et Fertilité, 41, 696-700. https://doi.org/10.1016/j.gyobfe.2013.08.019
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr
American Society of Clinical Oncology (1999) Update of Recommended Breast Cancer Surveillance Guidelines. Journal of Clinical Oncology, 17, 1080-1082.
Sebban, E. (2006) Pour la surveillance intensive après traitement du cancer du sein. Gynécologie Obstétrique et Fertilité, 34, 268-270.
Kamby, C. (1990) The Pattern of Metastases in Human Breast Cancer: Methodological Aspects and Influence of Prognostic Factors. Cancer Treatment Reviews, 17, 37-61. https://doi.org/10.1016/0305-7372(90)90075-Q
Aukema, T.S., Russell, N.S., Wesseling, J. and Rutgers, E.J. (2009) Extensive Soft Tissue Resection with Autologous Tissue Closure for Locally Recurrent Breast Cancer: Lasting Local Control and Acceptable Morbidity. European Journal of Surgical Oncology (EJSO), 35, 469-474. https://doi.org/10.1016/j.ejso.2008.12.015
Berenice, Q. (2014) Cancer du sein localement avancé: facteurs prédictifs de mastectomie après chimiothérapie néoadjuvante. A propos d'une série rétrospective de 247 patientes traitées à l'Institut Bergonié. Médecine humaine et pathologie, 1-85.
Early Breast Cancer Trialist’Collaborative Group. Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15 Year Survival: An Overview on the Randomized Trials. Lancet, 366, 2087-2106.
Chevallier, B., Heintzman, F. and Mosseri, V. (1989) Quels sont les facteurs pronostics du cancer du sein opérable sans envahissement ganglionnaire axillaire histologique? Résultats d’une analyse uni et multifactorielle. Bulletin du Cancer, 76, 51-60.
De La Rochefordière, A., Asslain, B. and Campana, F. (1993) Age Prognostic Factor in Premenopausal Breast Carcinoma. Lancet, 341, 1039-1043. https://doi.org/10.1016/0140-6736(93)92407-K
Guié, P., Dia, J.M., Saki, C., Bohoussou, E., Nguessan, E., Yao, I., et al. (2013) Dépistage des cancers du col de l’utérus et du sein: Connaissances et attitudes des femmes fonctionnaires vues en consultation au CHUT. International Medical Malpractice, 15, 141-145.
Ferrero, J.M., Pivot, X. and Namer, M. (1995) Association Mitoxantrone-Vinorelbine en première ligne thérapeutique dans le cancer du sein métastatique. Bulletin du Cancer, 82, 2002-2007.
Renaud, R., Gairard, B. and Bellocq, J.P. (1991) Le risque de métastases à distance In Cancer du sein: Surveillance après traitement. BREMOND A. Medition, 16-26.
Anhoux, A., Adoubi, I. and Echimane, K.A. (2002) Sites métastatiques du cancer du sein de la femme noire en Cote d’Ivoire. Espérance Médicale, 9, 622-625.
Harouna, D.Y., Boukary, I. and Kanou, H.M. (2002) Le cancer du sein de la femme au Niger. Médecine d'Afrique noire électronique, 1, 39-43.
Lansac, J. and Diouf, A. (1998) La surveillance d’une femme traitée pour cancer du sein. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 27, 21-23.
Mamby, C.C., Love, R.R. and Heaney, E. (1993) Metastatic Breast Cancer 39 Years after Primary Treatment. Wisconsin Medical Journal, 92, 567-569.
Tueche, S.G., Nguyen, H., Larsimont, D. and Andry, G. (1999) Lateonset of Tonsillar Metastasis from Breast Cancer. European Journal of Surgical Oncology, 25, 439-448. https://doi.org/10.1053/ejso.1999.0672
Belghiti, L., Chenguiti-Ansari, A. and Elaanine, M. (2002) Facteur pronostic dans le cancer du sein. Espérance Médicale, 9.
Zavetsky, J. and Gardner, B. (1996) Post Excisinal Recurrence of Carcinoma of the Breast. Journal of the American College of Surgeons, 182, 71-77.
Anvo, G. (2003) Rechutes métastatiques des cancers du sein traités à Abidjan: à propos de 80 cas colligés. ThèseMéd, Abidjan, 1-205.
Carter, C.L., Allen, C. and Henson, D. (1989) Relation of Tumor Size Lymphe Node Status, and Survival in 24740 Breast Cancer Cases. Cancer, 63, 181-187. https://doi.org/10.1002/1097-0142(19890101)63:1 3.0.CO;2-H
Host, H. and Brennhovd, I. (1975) Combined Surgery and Radiation Therapy versus Surgery Alone in Primary Mammary Carcinoma. Acta Radiologica, 14, 25-32.
Spielmann, M., Riofrio, M. and Zelek, L. (2000) Facteurs pronostiques du cancer du sein et facteurs prédictifs de la réponse au traitement. La Lettre du Cancérologue, 9, 29-35
Treilleux, I. and Brémond, A. (2002) Pronostic des cancers du sein. Encycl Méd Chir, 865-F-20, 1-7.
Contesso, G., Mouriesse, H. and Friedman, S. (1987) The Importance of Histologic Grade in Long-Term Prognosis of Breast Cancer: A Study of 1010 Patients, Uniformly Treated at the Institut Gustave-Roussy. Journal of Clinical Oncology, 5, 1378-1386. https://doi.org/10.1200/JCO.1987.5.9.1378
Hortobagyi, G.N., Kau, S.-W. and Buzdar, A.U. (2004) What Is the Prognosis of Patients with Operable Breast Cancer Five Years after Diagnosis? Proceedings of American Society of Clinical Oncology, 22, Abstract 585.
Dowseet, M., Nielsen, T.O., A’Hern, R., Bartlett, J., Coombes, R.C., Cuzick, J., et al. (2011) Assessment of Ki 67 in Breast Cancer: Recommendation from the International in Breast Cancer Working Group. Journal of the National Cancer Institute, 103, 1656-1664. https://doi.org/10.1093/jnci/djr393
Nieto, Y., Nawaz, S. and Cagnoni, P.J. (1999) Overexpression of Her 2/Neu (H2N), But Not P53 Mutations Is a Poor Prognostic Factor of High-Risk Primary Breast Cancer (HRPBC) Treated with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT). Proceedings of American Society of Clinical Oncology, 18, Abstract 290.
Wolff, A.C., Hammond, M.E., Hicks, D.G. and Dowseet, M. (2013) Recommendations for Human Epiderma Growth Factor Receptor 2 Testing in Breast Cancer. American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology, 31, 3997-4013. https://doi.org/10.1200/JCO.2013.50.9984